MCL1 and melanoma: Notably, combinations targeting both MCL-1 and BCL-2 (e.g., S63845 and Venetoclax) have proven efficacious and safe in clinical trials in both haematological (e.g., AML, T-cell ALL, MCL) and solid cancers (e.g., melanoma) [252].